4 月 17, 2023
HANCHORBIO ANNOUNCES US IND CLEARANCE FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES / 重大訊息 | 漢康生技首項新藥HCB101的國際多地區多中心臨床試驗獲美國FDA新藥臨床試驗(IND) 許可
4 月 13, 2023
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting 漢康生技成功舉辦SAB科學顧問委員會會議
HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.漢康生技（HanchorBio Inc.）於2023年3月29日在台北內湖總部成功舉辦了(SAB)科學顧問委員會會議。